
From: Steffelin, Edward [esteffelin@gsc.com]
Sent: Tuesday, February 27, 2007 9:33 AM
To: Ostrem, Peter L
Subject: FW: ABACUS 2007-AC1, Ltd. -- New Issue Announcement (144a/RegS)
Attachments: Portfolio Information 20070215 (6).xls; ABACUS 2007-AC1 Preliminary Term Sheet 20070226.; ABACUS 2007-AC1 Flipbook 20070226.pdf

I do not have to say how bad it is that you guys are pushing this thing.

Ed Steffelin
 212-884-6190
 GSC Partners

This email is intended only for the person or entity to which it is addressed and may contain information that is privileged, confidential or otherwise protected from disclosure. Dissemination, distribution or copying of this message or the information contained herein by anyone other than the intended recipient is prohibited. This email is intended for informational purposes is not a solicitation, offer or recommendation regarding the purchase or sale of securities or related financial instruments. If you received this message in error, please notify the sender by reply email and delete this message. Thank you.

From: Willing, Curtis [mailto:curtis.willing@gs.com]
Sent: Tuesday, February 27, 2007 9:22 AM
Subject: ABACUS 2007-AC1, Ltd. -- New Issue Announcement (144a/RegS)

ABACUS 2007-AC1, Ltd. -- New Issue Announcement (144a/RegS) (external)
 Sole Bookrunner & Lead Manager: Goldman, Sachs & Co.
 Portfolio Selection Agent: ACA Management, LLC
 \$2.0Bn Structured Product Synthetic Resecuritization
 (Portfolio of 90 Mdys Baa2 rated midprime and subprime RMBS Reference Obligat

Tranche	Mdys/S&P	Size (mm)	WAL (y)	%CapStr	%Subord	Guidance
SS	N/A	[1,100.00]	[3.9]	[55.00%]	[45.00%]	Call Desk
A	[Aaa/AAA]	[480.00]	[4.4]	[24.00%]	[21.00%]	1mL+TBD
B	[Aa2/AA]	[60.00]	[4.6]	[3.00%]	[18.00%]	1mL+TBD
C	[Aa3/AA-]	[100.00]	[4.7]	[5.00%]	[13.00%]	1mL+TBD
D	[A2/A]	[60.00]	[4.9]	[3.00%]	[10.00%]	1mL+TBD
First Loss	[NR/NR]	[200.00]	N/A	[10.00%]	[0.00%]	Call Desk

Attached - Termsheet, Debt Marketing Book, Initial Reference Portfolio

<<Portfolio Information 20070215 (6).xls>> <<ABACUS 2007-AC1 Preliminary Term Sheet 20070226.pc
 <<ABACUS 2007-AC1 Flipbook 20070226.pdf>>

Expected Timing:

Confidential Treatment Requested by Goldman Sachs

GS MBS

Preliminary OC - w/o March 5th
Price Guidance - w/o March 5th
Pricing - w/o March 26th

GS Structured Products Global Syndicate

Asia: Omar Chaudhary, Jay Lee & Hirotaka Sugioka +81 (3) 6437-7198

Europe: Mitch Resnick, Tets Ishikawa & Jessica Reis +44 (0)20 7774-3068

N. America: Bunty Bohra, Scott Wisenbaker, Robert Black, Scott Walter, Tony K
Malcolm Mui & Russell Brocato +1 (212) 902-7645

Risk Factors: An investment in the securities presents certain risks, please
the Preliminary Offering Circular for a description of certain risk factors.

Disclaimer:

This material has been prepared specifically for you and contains indicative
only. All material contained herein, including proposed terms and conditions
for discussion purposes only. Finalized terms and conditions are subject to f
discussion and negotiation. Goldman Sachs shall have no liability, contingent
otherwise, to the user or to third parties, for the quality, accuracy, timeli
continued availability or completeness of the data and information. Goldman S
does not provide accounting, tax or legal advice; such matters should be disc
with your advisors and or counsel. In addition, we mutually agree that, subje
applicable law, you may disclose any and all aspects of this material that ar
necessary to support any U.S. federal income tax benefits, without Goldman Sa
imposing any limitation of any kind.

This communication shall not constitute an offer to sell or the solicitation
offer to buy nor shall there be any sale of these securities in any State in
such offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such State. These securities a
being offered by the issuer and represent a new financing. A final prospectus
relating to these securities may be obtained from the offices of Goldman, Sac
Co., 85 Broad Street, New York, NY 10004.

Confidential Treatment Requested by Goldman Sachs

GS MBS